AOD9604 (Anti-Obesity Drug 9604) is a synthetic peptide consisting of the C-terminal fragment (amino acids 177-191) of human growth hormone (hGH), modified with an additional tyrosine residue for stability. Originally developed in the 1990s as a potential anti-obesity treatment, AOD9604 is studied for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) in adipose tissue, particularly in stubborn areas like the abdomen, without the anabolic, hyperglycemic, or insulin-desensitizing effects associated with full-length hGH. Preclinical animal studies and early-phase human trials (including a 2000s Australian study) demonstrated that AOD9604 could promote significant fat loss, improve lipid profiles, and enhance body composition when administered subcutaneously, with effects potentially independent of IGF-1 elevation or growth hormone axis stimulation. In research and anecdotal wellness contexts, AOD9604 is often used at doses of 300-500 mcg per day (typically injected once daily in the morning or before bed) for cycles of 4-12 weeks, with users reporting gradual reductions in body fat percentage, preserved muscle mass, and improved energy during calorie-restricted periods. It is frequently discussed as a \u201chGH fragment\u201d for non-hormonal fat-burning support, appealing to those seeking targeted weight management without the risks of full hGH therapy. However, AOD9604 is not FDA-approved for any therapeutic, weight loss, or medical use as of 2026\u2014it remains an investigational research peptide, with no large-scale, definitive clinical trials confirming long-term efficacy or safety in humans. The FDA has flagged it in certain contexts as a bulk substance presenting potential safety risks for compounding or human use. Reported side effects from user experiences are generally mild (injection-site irritation, headaches, fatigue, or mild nausea), but unknowns remain regarding immunogenicity, long-term metabolic effects, or potential interactions. It is prohibited by WADA for athletes and should never be used without supervision from a qualified healthcare provider experienced in peptides, as self-administration carries risks of contamination from unregulated sources, improper dosing, adverse reactions, or legal issues. Prioritize evidence-based weight management strategies\u2014consult a professional to assess suitability, source from reputable compounding pharmacies if considered under guidance (where permitted), and stay informed on regulatory or emerging research developments. AOD9604 is not a substitute for proven diet, exercise, or approved medical therapies.<\/p>","protected":false},"excerpt":{"rendered":"
Compre AOD9604, un fragmento pept\u00eddico sint\u00e9tico de la hormona del crecimiento humana, investigado por su potencial para promover la p\u00e9rdida de grasa y mejorar la composici\u00f3n corporal. Este agente en investigaci\u00f3n act\u00faa sobre el metabolismo de la grasa sin afectar significativamente los niveles de la hormona del crecimiento ni la sensibilidad a la insulina. Es popular en el \u00e1mbito del bienestar y la investigaci\u00f3n por favorecer la reducci\u00f3n de grasa espec\u00edfica, aunque no est\u00e1 aprobado por la FDA para uso humano.<\/p>","protected":false},"featured_media":1376,"template":"","meta":[],"product_brand":[],"product_cat":[224],"product_tag":[314,311,313,312,316,315],"class_list":{"0":"post-1375","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptide","7":"product_tag-anti-obesity-research-peptide","8":"product_tag-aod9604","9":"product_tag-fat-loss-peptide","10":"product_tag-hgh-fragment-peptide","11":"product_tag-investigational-weight-management-peptide","12":"product_tag-lipolytic-peptide","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable"},"yoast_head":"\n